Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: Robert Floyd who wrote (72)	4/17/1998 11:56:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 320

Received the following response from Connie Stout concerning the reason Aronex now expects results from the Zintevir trial in late 1998 (their Web page had said first half of 1998): "The delay is being caused due to slow patient enrollment. It is difficult to ask a patient on cocktail therapy to stop taking all medications and participate a new clinical trial. As a result, we are enrolling patients who for one reason or another are finding difficulty in the products available and are in need of a new medication." Re Atragen: "The Company anticipates completion of the pivotal Phase II trial in 1998 with the filing of an ATRAGEN New Drug Application for APL. Although the KS Phase II trial data was promising, we will not be focusing on that indication for future development. Our focus will be on other hematological indications such as AML and solid tumors such as prostate, non-Hodgkin's lymphoma, bladder, and head and neck." Phase 2 results for Annamycin: "Late 1998." Nyotran Phase 3 trials: (Web site says "complete in 1998."): "Our Phase III clinical trials are moving along as anticipated. They are expected to conclude at year end." AR102: "No, there is no partnering activity to date." AR726 and AR209: "Nothing to talk about at this time." It doesn't look like there will be much happening to move this stock before late in the year. Is there any reason to buy it before, say, August?